Medicare Enrolled
Dr. Phillip Aleksiejuk, MD
Rheumatology · Woodland Hills, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Aleksiejuk from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aleksiejuk?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aleksiejuk
Dr. Phillip Aleksiejuk is a rheumatology specialist in Woodland Hills, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Aleksiejuk performed 3,374 Medicare services across 697 unique beneficiaries.
Between the years covered by Open Payments, Dr. Aleksiejuk received a total of $11,756 from 35 pharmaceutical and/or device companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aleksiejuk is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 29% volume in CA
$11,756 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,374
Medicare services
Top 29% in CA for rheumatology
697
Unique beneficiaries
$33
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~281 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,140 | $19 | $45 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
651 | $0 | $3 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
531 | $100 | $280 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
310 | $1 | $5 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
102 | $138 | $370 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
78 | $14 | $47 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
62 | $12 | $50 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
60 | $1 | $2 |
| Monthly chronic pain management bundle A monthly service for chronic pain management that includes diagnosis, assessment, monitoring, and the development or revision of a person-centered care plan. |
59 | $68 | $160 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
58 | $30 | $100 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
58 | $64 | $190 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
54 | $59 | $170 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
44 | $53 | $144 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
34 | $3 | $6 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
34 | $1 | $30 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
30 | $25 | $120 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
28 | $121 | $343 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
26 | $57 | $202 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
15 | $43 | $117 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.9% high complexity
53.5% medium
40.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,756
Total received (2018-2024)
Avg $1,679/year across 7 years
Top 26% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
531
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,756 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,578
2023
$4,252
2022
$2,229
2021
$22
2020
$218
2019
$421
2018
$36
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$1,200
Amgen Inc.
$757
Novartis Pharmaceuticals Corporation
$311
UCB, Inc.
$291
GlaxoSmithKline, LLC.
$283
Janssen Biotech, Inc.
$239
Mallinckrodt Hospital Products Inc.
$193
Alexion Pharmaceuticals, Inc.
$183
Radius Health, Inc.
$150
Lilly USA, LLC
$148
Boehringer Ingelheim Pharmaceuticals, Inc.
$116
PFIZER INC.
$116
Kiniksa Pharmaceuticals International, plc
$108
AstraZeneca Pharmaceuticals LP
$102
Fidia Pharma USA Inc.
$86
Aurinia Pharma U.S., Inc.
$75
SCILEX PHARMACEUTICALS INC.
$50
E.R. Squibb & Sons, L.L.C.
$46
Fresenius Kabi USA, LLC
$33
Alnylam Pharmaceuticals Inc.
$24
SOBI, INC
$19
Zimmer Biomet Holdings, Inc.
$17
Octapharma USA, Inc.
$15
Teva Pharmaceuticals USA, Inc.
$15
Top 3 companies account for 49.5% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$1,647
Amgen Inc.
$1,513
Janssen Biotech, Inc.
$1,194
AbbVie Inc.
$1,172
Novartis Pharmaceuticals Corporation
$935
UCB, Inc.
$705
GlaxoSmithKline, LLC.
$630
Lilly USA, LLC
$469
PFIZER INC.
$438
AstraZeneca Pharmaceuticals LP
$372
Radius Health, Inc.
$316
Mallinckrodt Hospital Products Inc.
$302
Alexion Pharmaceuticals, Inc.
$292
Horizon Therapeutics plc
$223
Aurinia Pharma U.S., Inc.
$206
Fresenius Kabi USA, LLC
$162
Boehringer Ingelheim Pharmaceuticals, Inc.
$162
Mallinckrodt Enterprises LLC
$148
GENZYME CORPORATION
$125
Kiniksa Pharmaceuticals International, plc
$108
Octapharma USA, Inc.
$106
Merck Sharp & Dohme Corporation
$99
Fidia Pharma USA Inc.
$86
SOBI, INC
$58
DePuy Synthes Sales Inc.
$50
SCILEX PHARMACEUTICALS INC.
$50
E.R. Squibb & Sons, L.L.C.
$46
Alnylam Pharmaceuticals Inc.
$24
Gilead Sciences, Inc.
$21
Ultragenyx Pharmaceutical Inc.
$21
Zimmer Biomet Holdings, Inc.
$17
Janssen Pharmaceuticals, Inc
$16
AbbVie, Inc.
$16
Teva Pharmaceuticals USA, Inc.
$15
Dynavax Technologies Corporation
$12
Top 3 companies account for 37.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · Cimzia · Creon · ENTRESTO · EVENITY · EVUSHELD · Enbrel · FARXIGA · Gel-One Cross-linked Hyaluronate · HYMOVIS · Heplisav-B · IDACIO · ILARIS · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · MONOVISC · MOUNJARO · NEXPLANON · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ONPATTRO · ORENCIA · ORTHOVISC · Otezla · PENNSAID · REMICADE · RINVOQ · ROTATEQ · Repatha · SAPHNELO · SKYRIZI · STRENSIQ · TALTZ · TAVNEOS · TREMFYA · Truvada · Truxima · Tymlos · XARELTO · XELJANZ · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
158
Per 100K population
1.6
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - WOODLAND HILLS
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Aleksiejuk is a clinical cardiology specialist, with above-average Medicare volume (top 29% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Aleksiejuk experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Aleksiejuk performed 1,140 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aleksiejuk receive payments from pharmaceutical companies?
Yes. Dr. Aleksiejuk received a total of $11,756 from 35 companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aleksiejuk's costs compare to other rheumatologists in Woodland Hills?
Dr. Aleksiejuk's average Medicare payment per service is $33. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aleksiejuk) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Woodland Hills
Browse rheumatologists in Woodland Hills ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in CA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in CA
Which CA rheumatologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology